Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Trinity Legacy Partners LLC

Trinity Legacy Partners LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,497 shares of the company's stock after selling 3,878 shares during the quarter. Trinity Legacy Partners LLC's holdings in Johnson & Johnson were worth $4,555,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FDx Advisors Inc. raised its stake in shares of Johnson & Johnson by 11.5% during the fourth quarter. FDx Advisors Inc. now owns 4,213 shares of the company's stock valued at $609,000 after purchasing an additional 433 shares in the last quarter. Ardent Capital Management Inc. raised its stake in shares of Johnson & Johnson by 2.1% during the fourth quarter. Ardent Capital Management Inc. now owns 149,955 shares of the company's stock valued at $21,686,000 after purchasing an additional 3,096 shares in the last quarter. Nicholson Wealth Management Group LLC raised its stake in shares of Johnson & Johnson by 76.8% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 11,378 shares of the company's stock valued at $1,645,000 after purchasing an additional 4,944 shares in the last quarter. Mattern Capital Management LLC raised its stake in shares of Johnson & Johnson by 4.1% during the fourth quarter. Mattern Capital Management LLC now owns 51,095 shares of the company's stock valued at $7,389,000 after purchasing an additional 2,031 shares in the last quarter. Finally, ING Groep NV raised its stake in shares of Johnson & Johnson by 58.5% during the fourth quarter. ING Groep NV now owns 524,810 shares of the company's stock valued at $75,898,000 after purchasing an additional 193,689 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 1.7 %

NYSE:JNJ opened at $162.35 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock's 50-day moving average is $148.93 and its two-hundred day moving average is $155.86. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio is 74.59%.

Analysts Set New Price Targets

Several equities research analysts have commented on JNJ shares. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Finally, Bank of America dropped their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.